Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $38.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 186.79% from the company’s current price. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2029 earnings at ($0.69) EPS.

Separately, Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Up 10.4 %

NASDAQ PVLA opened at $13.25 on Friday. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32. The stock has a market cap of $17.49 million, a P/E ratio of -1.10 and a beta of 0.61.

Insiders Place Their Bets

In other Palvella Therapeutics news, Director George M. Jenkins purchased 4,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was purchased at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares in the company, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.39% of the company’s stock.